Title:
COMBINATION THERAPIES COMPRISING A SOS1 INHIBITOR AND AN EGFR INHIBITOR
Document Type and Number:
WIPO Patent Application WO/2023/196086
Kind Code:
A3
Abstract:
The present invention relates to combination therapies for treating cancers associated with genetic alterations of the MAPK pathway and/or EGFR In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a SOS1 inhibitor and an EGFR inhibitor, pharmaceutical compositions comprising a such compositions, kits comprising such compositions and methods of use therefor.
Inventors:
HALING JACOB (US)
KHARE SHILPI (US)
KHARE SHILPI (US)
Application Number:
PCT/US2023/015097
Publication Date:
December 07, 2023
Filing Date:
March 13, 2023
Export Citation:
Assignee:
MIRATI THERAPEUTICS INC (US)
International Classes:
A61K31/395; A61K31/16; A61K31/407; A61K31/33
Domestic Patent References:
| WO2016077793A1 | 2016-05-19 | |||
| WO2022083657A1 | 2022-04-28 | |||
| WO2022266015A1 | 2022-12-22 |
Foreign References:
| US20210188857A1 | 2021-06-24 | |||
| US7842805B2 | 2010-11-30 |
Other References:
LE TRI, GERBER DAVID: "Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used?", CANCERS, CH, vol. 11, no. 3, CH , pages 366, XP093118426, ISSN: 2072-6694, DOI: 10.3390/cancers11030366
Attorney, Agent or Firm:
POLYAKOV, Mark, V. et al. (US)
Download PDF: